These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31776827)

  • 1. Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review.
    Charton E; Cuer B; Cottone F; Efficace F; Touraine C; Hamidou Z; Fiteni F; Bonnetain F; Woronoff-Lemsi MC; Bascoul-Mollevi C; Anota A
    Qual Life Res; 2020 Apr; 29(4):867-878. PubMed ID: 31776827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. %TTD and %TUDD: New SAS macro programs to calculate the survival data of the time to deterioration for patient-reported outcomes data in oncology.
    Charton E; Falcoz A; François E; Touraine C; Bachet JB; Louvet C; Hamidou Z; Bascoul-Mollevi C; Anota A
    Comput Methods Programs Biomed; 2022 Feb; 214():106537. PubMed ID: 34879326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inclusion of older patients with cancer in randomised controlled trials with patient-reported outcomes: a systematic review.
    Sparano F; Aaronson NK; Sprangers MAG; Fayers P; Pusic A; Kieffer JM; Cottone F; Rees J; Pezold M; Anota A; Charton E; Vignetti M; Wan C; Blazeby J; Efficace F
    BMJ Support Palliat Care; 2019 Dec; 9(4):451-463. PubMed ID: 31719051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review.
    Chakraborty R; Cannella L; Cottone F; Efficace F
    Lancet Haematol; 2020 Dec; 7(12):e892-e901. PubMed ID: 33242446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time to deterioration of patient-reported outcomes in non-small cell lung cancer: exploring different definitions.
    Walding A; Skaltsa K; Casamayor M; Rydén A
    Qual Life Res; 2022 Aug; 31(8):2535-2543. PubMed ID: 35099678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing the patient voice in prostate cancer research: Systematic review on the use of patient-reported outcomes in randomized controlled trials to support clinical decision-making.
    Van Hemelrijck M; Sparano F; Moris L; Beyer K; Cottone F; Sprangers M; Efficace F
    Cancer Med; 2020 Jun; 9(12):4039-4058. PubMed ID: 32333639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review.
    Van Hemelrijck M; Sparano F; Josephs D; Sprangers M; Cottone F; Efficace F
    BMC Urol; 2019 Sep; 19(1):86. PubMed ID: 31521149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?
    Anota A; Hamidou Z; Paget-Bailly S; Chibaudel B; Bascoul-Mollevi C; Auquier P; Westeel V; Fiteni F; Borg C; Bonnetain F
    Qual Life Res; 2015 Jan; 24(1):5-18. PubMed ID: 24277234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.
    Pe M; Dorme L; Coens C; Basch E; Calvert M; Campbell A; Cleeland C; Cocks K; Collette L; Dirven L; Dueck AC; Devlin N; Flechtner HH; Gotay C; Griebsch I; Groenvold M; King M; Koller M; Malone DC; Martinelli F; Mitchell SA; Musoro JZ; Oliver K; Piault-Louis E; Piccart M; Pimentel FL; Quinten C; Reijneveld JC; Sloan J; Velikova G; Bottomley A;
    Lancet Oncol; 2018 Sep; 19(9):e459-e469. PubMed ID: 30191850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal health-related quality of life analysis in oncology with time to event approaches, the STATA command qlqc30_TTD.
    Bascoul-Mollevi C; Savina M; Anota A; Barbieri A; Azria D; Bonnetain F; Gourgou S
    Comput Methods Programs Biomed; 2018 May; 158():153-159. PubMed ID: 29544781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021.
    Efficace F; Cottone F; Sparano F; Caocci G; Vignetti M; Chakraborty R
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):442-459. PubMed ID: 35183476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating the impact of open label design on patient-reported outcome results in prostate cancer randomized controlled trials.
    Mouillet G; Efficace F; Thiery-Vuillemin A; Charton E; Van Hemelrijck M; Sparano F; Anota A
    Cancer Med; 2020 Oct; 9(20):7363-7374. PubMed ID: 32846465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient reported outcomes in randomized controlled cancer trials in advanced disease: a structured literature review.
    Weingärtner V; Dargatz N; Weber C; Mueller D; Stock S; Voltz R; Gaertner J
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):821-9. PubMed ID: 26959869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes in randomized clinical trials of systemic therapy for advanced soft tissue sarcomas in adults: A systematic review.
    Roets E; van der Graaf W; van Riet BHG; Haas RL; Younger E; Sparano F; Wilson R; van der Mierden S; Steeghs N; Efficace F; Husson O
    Crit Rev Oncol Hematol; 2024 May; 197():104345. PubMed ID: 38582227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of open-label versus blinded study design on patient-reported outcomes data in randomized clinical trials of immunotherapy in advanced or metastatic cancer patients: a systematic review.
    Anota A; Pozet A; Lemasson H; Cotté FE; Falcoz A; Eberst G; Mouillet G; Guerzider S; Charton É; Westeel V
    Qual Life Res; 2022 Mar; 31(3):645-657. PubMed ID: 34283382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Past and Current Practice of Patient-Reported Outcome Measurement in Randomized Cancer Clinical Trials: A Systematic Review.
    Giesinger JM; Efficace F; Aaronson N; Calvert M; Kyte D; Cottone F; Cella D; Gamper EM
    Value Health; 2021 Apr; 24(4):585-591. PubMed ID: 33840437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes in head and neck and thyroid cancer randomised controlled trials: A systematic review of completeness of reporting and impact on interpretation.
    Mercieca-Bebber RL; Perreca A; King M; Macann A; Whale K; Soldati S; Jacobs M; Efficace F
    Eur J Cancer; 2016 Mar; 56():144-161. PubMed ID: 26851406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer.
    Zhou Z; Tang DH; Xie J; Ayyagari R; Wu E; Niravath PA
    Adv Ther; 2017 Dec; 34(12):2566-2584. PubMed ID: 29143928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.
    Pérol M; Pavlakis N; Levchenko E; Platania M; Oliveira J; Novello S; Chiari R; Moran T; Mitry E; Nüesch E; Liu T; Balas B; Konopa K; Peters S
    Lung Cancer; 2019 Dec; 138():79-87. PubMed ID: 31654838
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.